Association Between Hypertension and the Prevalence of Liver Steatosis and Fibrosis

Overview

Journal BMC Endocr Disord

Publisher Biomed Central

Specialty Endocrinology

Date 2023 Apr 20

PMID 37081417

Authors

Huanjie Fu

Hao Yu

Yisheng Zhao

Jinhong Chen

Zhichao Liu

Affiliations

Soon will be listed here.

Abstract

Background: Hypertension (HTN) and non-alcoholic fatty liver disease (NAFLD) frequently coexist and share pathophysiological symptoms. Based on the liver stiffness measurement and controlled attenuation parameter obtained by performing liver transient ultrasound elastography (TUE), we determined the relationship between HTN status and the rates of liver steatosis and fibrosis in this study.

Methods: To perform this cross-sectional study, data were obtained from the National Health and Nutrition Examination Survey for 2017-March 2020 Pre-pandemic cycle. The relationship between HTN and the rates of liver steatosis and fibrosis was analyzed by constructing a multivariate logistic regression model. The VCTE was performed using a FibroScan® system (model 502, V2 Touch), and CAP was measured at ≥ 274 dB/m for liver steatosis, and the LSM result (median, ≥ 8 kPa) confirmed fibrosis. We also conducted subgroup analyses based on the age, sex, ethnicity, and body mass index (BMI) of the patients.

Results: In total, 4,705 participants were recruited, including 2,287 participants with HTN and 2,418 without HTN. After adjusting possible confounders, HTN was positively related to the liver steatosis rate (OR = 1.4, 95% CI: 1.1-1.8). Such HTN-associated prevalence was higher among males (OR = 1.6, 95% CI: 1.1-2.2), non-Hispanic African American individuals (OR = 2.1, 95% CI: 1.1-3.7), and participants with BMI ≥ 25 < 30 kg/m (OR = 1.7, 95% CI: 1.1-2.5). Additionally, HTN was positively associated with the fibrosis rate (OR = 2.0, 95% CI: 1.3-3.0), especially among females (OR = 2.6, 95% CI: 1.3-5.2), among individuals who were 40-59 years old (OR = 2.1, 95% CI: 1.0-4.3), 60-80 years old (OR = 2.4, 95% CI:1.3-4.6), non-Hispanic Caucasian (OR = 2.9, 95% CI: 1.5-5.6), among those with BMI ≥ 25 < 30 kg/m (OR = 3.0, 95% CI: 1.1-8.2), and those with BMI ≥ 30 kg/m (OR = 2.1, 95% CI: 1.4-3.2).

Conclusion: The results of this study revealed that HTN status was associated with higher rates of liver steatosis and fibrosis, particularly in subjects with BMI ≥ 25 kg/m. The ethnicity of the participants also had an impact on the relationship.

Citing Articles

Association of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors.

Elgretli W, Shengir M, Sasson S, Ramanakumar A, Cinque F, Ballestreros L J Viral Hepat. 2025; 32(2):e70004.

PMID: 39868661 PMC: 11771651. DOI: 10.1111/jvh.70004.

Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) and mortality among survivors of liver cirrhosis: a prospective cohort study.

Fotros D, Hekmatdoost A, Pashayee-Khamene F, Karimi S, Ahmadzadeh S, Saberifiroozi M Nutr J. 2025; 24(1):15.

PMID: 39856705 PMC: 11762518. DOI: 10.1186/s12937-025-01086-9.

Dietary acid load and cirrhosis-related mortality: a prospective cohort study.

Pashayee-Khamene F, Heidari Z, Fotros D, Hekmatdoost A, Karimi S, Ahmadzadeh S Sci Rep. 2024; 14(1):3675.

PMID: 38355888 PMC: 10867032. DOI: 10.1038/s41598-024-53882-8.

References

Boccuto L, Abenavoli L . Genetic and Epigenetic Profile of Patients With Alcoholic Liver Disease. Ann Hepatol. 2017; 16(4):490-500. DOI: 10.5604/01.3001.0010.0274. View

Petersen M, Shulman G . Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev. 2018; 98(4):2133-2223. PMC: 6170977. DOI: 10.1152/physrev.00063.2017. View

Chen J, Hu P, Wang Y, Zhu Z . Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years. BMC Endocr Disord. 2022; 22(1):128. PMC: 9107256. DOI: 10.1186/s12902-022-01046-y. View

Low Wang C, Hess C, Hiatt W, Goldfine A . Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation. 2016; 133(24):2459-502. PMC: 4910510. DOI: 10.1161/CIRCULATIONAHA.116.022194. View

Johnson C, Paulose-Ram R, Ogden C, Carroll M, Kruszon-Moran D, Dohrmann S . National health and nutrition examination survey: analytic guidelines, 1999-2010. Vital Health Stat 2. 2014; (161):1-24. View

Ciardullo S, Monti T, Grassi G, Mancia G, Perseghin G . Blood pressure, glycemic status and advanced liver fibrosis assessed by transient elastography in the general United States population. J Hypertens. 2021; 39(8):1621-1627. PMC: 9904436. DOI: 10.1097/HJH.0000000000002835. View

Masarone M, Rosato V, Dallio M, Gravina A, Aglitti A, Loguercio C . Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev. 2018; 2018:9547613. PMC: 6016172. DOI: 10.1155/2018/9547613. View

Paik J, Deshpande R, Golabi P, Younossi I, Henry L, Younossi Z . The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019; 51(2):291-304. DOI: 10.1111/apt.15580. View

Targher G, Corey K, Byrne C . NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab. 2020; 47(2):101215. DOI: 10.1016/j.diabet.2020.101215. View

10.

Dyson J, Anstee Q, McPherson S . Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014; 5(3):211-218. PMC: 4078666. DOI: 10.1136/flgastro-2013-100403. View

11.

Gangireddy V, Pilkerton C, Xiang J, Tinajero R, Ashcraft A . Hepatic Fibrosis and Steatosis in Metabolic Syndrome. J Obes Metab Syndr. 2022; 31(1):61-69. PMC: 8987451. DOI: 10.7570/jomes21062. View

12.

Eddowes P, Sasso M, Allison M, Tsochatzis E, Anstee Q, Sheridan D . Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019; 156(6):1717-1730. DOI: 10.1053/j.gastro.2019.01.042. View

13.

Powell E, Wong V, Rinella M . Non-alcoholic fatty liver disease. Lancet. 2021; 397(10290):2212-2224. DOI: 10.1016/S0140-6736(20)32511-3. View

14.

Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal W, Strowig T . Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012; 482(7384):179-85. PMC: 3276682. DOI: 10.1038/nature10809. View

15.

Kasper P, Martin A, Lang S, Kutting F, Goeser T, Demir M . NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2020; 110(7):921-937. PMC: 8238775. DOI: 10.1007/s00392-020-01709-7. View

16.

Heredia N, Zhang X, Balakrishnan M, Hwang J, Thrift A . Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among Hispanic/Latinos adults in the U.S. Ethn Health. 2022; 28(2):299-312. PMC: 9307692. DOI: 10.1080/13557858.2022.2027883. View

17.

Abenavoli L, Pellicano R, Boccuto L . Role of genetics and metabolism in non-alcoholic fatty liver disease. Panminerva Med. 2018; 60(2):41-43. DOI: 10.23736/S0031-0808.18.03418-3. View

18.

Ciardullo S, Monti T, Sala I, Grassi G, Mancia G, Perseghin G . Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories. Hypertension. 2020; 76(2):562-568. DOI: 10.1161/HYPERTENSIONAHA.120.15220. View

19.

Yu E, Golshan S, Harlow K, Angeles J, Durelle J, Goyal N . Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity. J Pediatr. 2018; 207:64-70. PMC: 6440815. DOI: 10.1016/j.jpeds.2018.11.021. View

20.

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View